GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk 13 March
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026 21 January
